Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia

OBJECTIVES: Lefamulin is a semi-synthetic intravenous (iv) and oral pleuromutilin antibiotic active against community-acquired bacterial pneumonia (CABP) pathogens. Pharmacokinetic/pharmacodynamic (PK/PD) target attainment analyses were carried out to evaluate lefamulin 150 mg iv q12h and 600 mg ora...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Antimicrob Chemother
Päätekijät: Bhavnani, Sujata M, Zhang, Li, Hammel, Jeffrey P, Rubino, Christopher M, Bader, Justin C, Sader, Helio S, Gelone, Steven P, Wicha, Wolfgang W, Ambrose, Paul G
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2019
Aiheet:
Supplement Papers
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6449570/
https://ncbi.nlm.nih.gov/pubmed/30949705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkz089
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia